All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Urology Product Name: RVT-901
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Urovant Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Details:
Under the terms of the agreement, Sunovion will deploy its multi-specialty sales force to bring vibegron to primary care physicians (PCP). In support of this effort, Sunovion will provide sales and marketing activities targeting the PCP segment through March 31, 2026.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron,Tolterodine Tartrate
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
Urovant Sciences a family company of Sumitovant announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two Phase 1 trials.